Your pancreas releases amylin with insulin after you eat. Amylin helps signal fullness, slows how quickly food leaves the stomach, and helps limit the rise in blood sugar after a meal. Researchers are studying whether medicines that use this pathway can help manage weight. What a headline calls “an amylin drug” might be one medicine being tested by itself, a combination with a GLP-1 medicine, or one molecule designed to act on several receptors.
How does amylin differ from GLP-1?
Amylin and GLP-1 are different hormones with different receptors. Both influence appetite and how quickly the stomach empties. Amylin is released by the pancreas and helps restrain the post-meal release of glucagon, a signal that tells the liver to put glucose into the blood. GLP-1 is released mainly from the gut and, among other effects, helps increase insulin release when glucose is elevated. The overlap in fullness and digestion is one reason to study the pathways together. It also means researchers need to evaluate tolerability in the actual combination, alongside any weight benefit. Pramlintide label, clinical pharmacology and FDA-reviewed Wegovy prescribing information, clinical pharmacology.
Is there an approved amylin medicine for weight loss?
Pramlintide, sold as Symlin, received FDA approval for glucose management in certain people with type 1 or type 2 diabetes who use mealtime insulin and have not reached their glucose goal despite optimized insulin treatment. Its approval was for use alongside insulin for that purpose. It was never approved for weight loss. The Drugs@FDA record lists Symlin presentations as discontinued, so an old approval date or an online label is insufficient evidence that it is currently sold.
The pramlintide label carries a boxed warning for severe low blood sugar with insulin, particularly in type 1 diabetes. It calls for clinician-directed mealtime insulin changes and frequent glucose checks when starting treatment. That's a safety condition for pramlintide with insulin. The newer amylin research has its own studies, risks and regulatory decisions.
What are researchers testing for weight management?
Read the name in the headline before you read the percentage. The name tells you how many medicines were given and which effects the trial is designed to test.
| Name or approach | What is being tested | U.S. research or regulatory status |
|---|---|---|
| Cagrilintide, petrelintide, or eloralintide | An individual amylin-based medicine, which can be evaluated on its own. Receptor activity differs among the three. | Investigational. Cagrilintide has phase 3 data, including a stand-alone trial arm. Petrelintide and eloralintide have entered phase 3 programs. |
| CagriSema | Two medicines in one combination: cagrilintide with semaglutide. | Investigational. Novo Nordisk submitted its U.S. weight-management application in December 2025. The sponsor's November 16, 2026 update lists it as unapproved. |
| Zenagamtide, previously called amycretin | One molecule with activity at GLP-1, amylin, and calcitonin receptors. | Investigational, with phase 3 research underway and injectable and oral forms in development. |
Sources: Novo Nordisk's November 2026 update, Zealand Pharma's petrelintide phase 3 announcement, Lilly's eloralintide trial record, and zenagamtide phase 3 trial registration.
“Studied on its own” describes a trial arm. It does not tell you the number of receptors the medicine can activate. For example, cagrilintide activates amylin and calcitonin receptors, while eloralintide is being developed as a selective amylin receptor agonist. Adding semaglutide in CagriSema adds a separate drug with GLP-1 activity. Zenagamtide brings GLP-1 activity into the same molecule. You would need a direct comparison to tell whether that design difference changes weight loss or side effects. Cagrilintide and zenagamtide receptor descriptions and eloralintide trial report.
How can you tell which ingredient contributed to a result?
A combination beating placebo can show a benefit for the combination. To find out what each ingredient contributes, look for a trial with additional groups receiving the individual ingredients. In REDEFINE 1, researchers included cagrilintide alone and semaglutide alone alongside the combination and placebo. That design allows comparisons in people recruited for the same trial and followed over the same period. Find the actual comparisons and results in our CagriSema trial guide.
A percentage from that trial still cannot rank CagriSema against another molecule from a shorter trial in different participants. Check the doses, time frame, and whether the analysis counted outcomes after people stopped treatment. A trial report says what happened under its study conditions. An application means the FDA has been asked to review a specific use. For products and forms with current indications, see the GLP-1 medications list.

About the author
Maya Lee
Glowise Senior GLP-1 Content Editor
Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.
She helps readers ask better questions and keep the details relevant to a care conversation together.
See more Glowise on Google
Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.


